Rapid and sustained response to tofacitinib in a patient with anal pyoderma gangrenosum under immunosuppression and bone marrow suppression

Tofacitinib may offer a rapid, effective, and well-tolerated treatment alternative in cases of refractory PG, even when layered onto preexisting immunosuppressive regimens. This case highlights the potential of JAK inhibitors as targeted therapy in complex PG presentations and supports their further clinical evaluation.